A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

ObjectiveTo explore the role of chidamide, decitabine plus priming regimen in the salvage treatment of relapsed/refractory acute myeloid leukemia.MethodsA clinical trial was conducted in relapsed/refractory acute myeloid leukemia patients using chidamide, decitabine, cytarabine, idarubicin, and gran...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jia Yin, Chao-Ling Wan, Ling Zhang, Hao Zhang, Lian Bai, Hai-Xia Zhou, Ming-Zhu Xu, Li-Yun Chen, Chong-Sheng Qian, Hui-Ying Qiu, Su-Ning Chen, Xiao-Wen Tang, De-Pei Wu, Yan-Ming Zhang, Ai-Ning Sun, Sheng-Li Xue
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2021-09-01
Serie:	Frontiers in Oncology
Soggetti:	epigenomics histone deacetylase inhibitor (HDACi) CDIAG regimen relapsed/refractory acute myeloid leukemia salvage therapy
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2021.726926/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!